Literature DB >> 30794086

Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein.

Jessica E Chukwu1, Erin E Congdon2, Einar M Sigurdsson2, Xiang-Peng Kong1.   

Abstract

Targeting tau with immunotherapies is currently the most common approach taken in clinical trials of patients with Alzheimer's disease. The most prominent pathological feature of tau is its hyperphosphorylation, which may cause the protein to aggregate into toxic assemblies that collectively lead to neurodegeneration. Of the phospho-epitopes, the region around Ser396/Ser404 has received particular attention for therapeutic targeting because of its prominence and stability in diseased tissue. Herein, we present the antigen-binding fragment (Fab)/epitope complex structures of three different monoclonal antibodies (mAbs) that target the pSer404 tau epitope region. Most notably, these structures reveal an antigen conformation similar to a previously described pathogenic tau epitope, pSer422, which was shown to have a β-strand structure that may be linked to the seeding core in tau oligomers. In addition, we have previously reported on the similarly ordered conformation observed in a pSer396 epitope, which is in tandem with pSer404. Our data are the first Fab structures of mAbs bound to this epitope region of the tau protein and support the existence of proteopathic tau conformations stabilized by specific phosphorylation events that are viable targets for immune modulation.

Entities:  

Keywords:  Alzheimer’s disease; Monoclonal antibody; antibody-antigen complex; phospho-epitope; tau protein

Mesh:

Substances:

Year:  2019        PMID: 30794086      PMCID: PMC6512906          DOI: 10.1080/19420862.2019.1574530

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  58 in total

1.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

2.  Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain.

Authors:  Stefan Barghorn; Peter Davies; Eckhard Mandelkow
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

3.  Template-assisted filament growth by parallel stacking of tau.

Authors:  Martin Margittai; Ralf Langen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

4.  Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.

Authors:  Bridget Allen; Esther Ingram; Masaki Takao; Michael J Smith; Ross Jakes; Kanwar Virdee; Hirotaka Yoshida; Max Holzer; Molly Craxton; Piers C Emson; Cristiana Atzori; Antonio Migheli; R Anthony Crowther; Bernardino Ghetti; Maria Grazia Spillantini; Michel Goedert
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

5.  Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration.

Authors:  T Bussière; P R Hof; C Mailliot; C D Brown; M L Caillet-Boudin; D P Perl; L Buée; A Delacourte
Journal:  Acta Neuropathol       Date:  1999-03       Impact factor: 17.088

6.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

7.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

Authors:  D P Hanger; K Hughes; J R Woodgett; J P Brion; B H Anderton
Journal:  Neurosci Lett       Date:  1992-11-23       Impact factor: 3.046

8.  Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau.

Authors:  E M Mandelkow; G Drewes; J Biernat; N Gustke; J Van Lint; J R Vandenheede; E Mandelkow
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

9.  Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure.

Authors:  John Berriman; Louise C Serpell; Keith A Oberg; Anthony L Fink; Michel Goedert; R Anthony Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

10.  Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies.

Authors:  I Ferrer; I Hernández; M Boada; A Llorente; M J Rey; A Cardozo; M Ezquerra; B Puig
Journal:  Acta Neuropathol       Date:  2003-08-29       Impact factor: 17.088

View more
  1 in total

1.  Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model.

Authors:  Dov B Shamir; Yan Deng; Qian Wu; Swananda Modak; Erin E Congdon; Einar M Sigurdsson
Journal:  Front Neurol       Date:  2020-11-26       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.